Clinical trials: Immune
Waldenstrom Macroglobulinemia, DASATINIB
Dasatinib In Waldenström Macroglobulinemia
This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations
- Trial name
- NCT04115059
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Jorge J. Castillo, MD
Systemic Lupus Erythematosus, Depression
LUPUS Brain: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE
The purpose of this study is to investigate the effects of a type of non-invasive transcranial alternating current stimulation (tACS) on patients diagnosed with systemic lupus erythematosus (SLE) who are experiencing depression.
- Trial name
- NCT04141046
- Testing
- XCSITE100 Stimulator - Individualized theta-tACS, XCSITE100 Stimulator - Individualized alpha-tACS
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Asthma
Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.
The purpose of this study is to assess peak FEV1 of two doses of QVM149 compared to a fixed-dose combination of salmeterol/fluticasone (50/500μg b.i.d.) and to characterize the respective 24 hour bronchodilator effect profiles in…
- Trial name
- NCT03063086
- Testing
- QVM149 150/50/80 μg o.d., QVM149 150/50/160 μg o.d., salmeterol/fluticasone FDC 50/500 μg b.i.d.
- Where
- 12 sites in Bulgaria, China and 4 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma
- Trial name
- NCT00867529
- Testing
- rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Fred Hutchinson Cancer Center
CIDP, Chronic Inflammatory Demyelinating Polyneuropathy
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- NCT00962429
- Testing
- lipoic acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Oregon Health and Science University
Food Allergy, Peanut Allergy
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
The primary objective of this study is to determine whether allowing ingestion of sub-threshold amounts of peanut in those with a high threshold (tolerate at least 143 mg peanut protein on supervised double-blind…
- Trial name
- CAFETERIA (NCT03907397)
- Testing
- Peanut Protein, Continued peanut avoidance
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Scott Sicherer
Multiple Sclerosis
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS).
- Trial name
- OPTIMUM-LT (NCT03232073)
- Testing
- Ponesimod
- Where
- 148 sites in United States, Belarus and 26 more
- Volunteers
- 877 people
- Sponsor
- Actelion
Multiple Myeloma in Relapse, Stage II Multiple Myeloma
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
This phase II trial is studying how well giving bevacizumab together with lenalidomide and dexamethasone works in treating patients with relapsed or refractory stage II or stage III multiple myeloma.
- Conditions
- Multiple Myeloma in Relapse, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00410605
- Testing
- bevacizumab, lenalidomide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Lymphoma, Non-Hodgkin
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00396266
- Testing
- G-CSF Plus Plerixafor
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00070018
- Testing
- rituximab, Cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
This phase II trial studies the side effects and how well vorinostat works in treating patients with primary cutaneous T-cell lymphoma.
- Conditions
- Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II, Cutaneous T-cell Lymphoma Stage III, Cutaneous T-cell Lymphoma Stage IV
- Trial name
- NCT00958074
- Testing
- vorinostat, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Washington
Antiphospholipid Syndrome
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
RITuximab AntiphosPholipid Syndrome (RITAPS) Study is designed to evaluate whether a medication called rituximab would reduce the signs and symptoms of antiphospholipid antibody (aPL) -related certain clinical problems.
- Trial name
- RITAPS (NCT00537290)
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Hospital for Special Surgery, New York
Type 1 Diabetes
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
This study was designed to determine which maintenance immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a…
- Trial name
- NCT00533442
- Testing
- Rapamycin, Mycophenolate Mofetil, Tacrolimus
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Miami
Multiple Sclerosis, Relapsing-Remitting
Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)
This study will enroll about 66 participants who experienced a relapse of RRMS that steroids did not help. The doctor will put participants into a treatment group.
- Trial name
- OPTIONS (NCT03126760)
- Testing
- Acthar Gel
- Where
- 22 sites in United States
- Volunteers
- 35 people
- Sponsor
- Mallinckrodt ARD LLC
Healthy Volunteers, Diabetes Mellitus, Type 1
Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass
Type 1 diabetes mellitus (T1DM) develops when there is impaired insulin production due to loss of insulin producing cells (beta cells).
- Trial name
- NCT02236754
- Testing
- 18 F-FP-DTBZ, PET Scanning
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This is a two-part trial, with three panels per part.
- Trial name
- NCT03095651
- Testing
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis.
- Trial name
- NCT00661661
- Testing
- CP-690,550
- Where
- 56 sites in Japan
- Volunteers
- 487 people
- Sponsor
- Pfizer
HIV Infections
A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers
This first-in-human study will evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of the HIV entry inhibitor CPT31 (cholesterol-PIE12-2-trimer) in healthy adults.
- Trial name
- NCT04672083
- Testing
- CPT31
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Navigen, Inc.
Rheumatoid Arthritis
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
This open-label, multi-center, two-arm, uncontrolled and non-randomized study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT01332994
- Testing
- rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra]
- Where
- 83 sites in Germany
- Volunteers
- 519 people
- Sponsor
- Hoffmann-La Roche
Asthma
Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study.
- Trial name
- NCT03560466
- Testing
- Dupilumab (SAR231893/REGN668), Asthma controller therapies (incl. prednisone/prednisolone), Asthma reliever therapies
- Where
- 81 sites in United States, Argentina and 16 more
- Volunteers
- 378 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.